EGFR and breast cancer: The importance of Y845 phosphorylation and CoxII engagement of EGFR in mitochondria is suggested by the fact that wild-type EGFR, but not Y845 mutant of EGFR, translocates to mitochondria where it physically associates with CoxII, and that such interactions contribute to an increase in survival of MDA-MB-231 breast cancer cells under serum-deprived or adriamycin-treated “pro-apoptotic” conditions [56,57].